Scientists investigate why cancer drug loses its punch
NCT ID NCT07199959
Summary
This study aims to understand why some lung cancers with a specific genetic change (ROS1 fusion) eventually stop responding to the targeted drug entrectinib. Researchers will analyze tissue and blood samples from patients who have taken entrectinib as part of their regular care. The goal is to identify the biological mechanisms of drug resistance to help guide future treatment strategies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan university shanghai cancer center
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.